Lawrence Tallon, Chief Executive Officer, Medicines and Healthcare products Regulatory Agency (MHRA)

The case for faster regulation is familiar. Britain wants to attract life sciences investment, accelerate access to innovative treatments and make medical technology easier to bring to market. Since becoming chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025, Lawrence Tallon has been responsible for advancing these ambitions while protecting public health. His October safety roundup offers a practical measure of that balance: what happens when new evidence changes the assessment of a product already in use?

Tallon brings experience shaped by healthcare delivery, not regulation alone. Before joining the MHRA, he served as Deputy Chief Executive of Guy’s and St Thomas’ NHS Foundation Trust, with responsibilities spanning strategy, technology, innovation and organisational change. During the COVID-19 pandemic, he played a role in ensuring access to essential medical equipment. In 2021, he led the trust’s merger with the Royal Brompton and Harefield hospitals. Earlier, he held strategy and performance responsibilities at University Hospitals Birmingham and managed the Shelford Group of leading NHS teaching hospitals.

Tallon’s experience gives him insight into how regulatory decisions translate into real-world clinical practice. His priority is to ensure that regulation supports manufacturers in bringing products to market while enabling clinicians to use them safely and effectively.

Tallon’s approach centres on making regulation more agile and proportionate while retaining scientific rigour. Greater use of automation and artificial intelligence, international collaboration and risk-based assessments could help reduce unnecessary delays. However, faster approval is only one part of the regulatory process. Monitoring products after they reach patients is equally important, particularly when new evidence raises safety concerns.

October’s roundup illustrates why. The MHRA withdrew the UK marketing authorisation for the IXCHIQ chikungunya vaccine after concluding that its benefits no longer outweighed its risks. Healthcare professionals were instructed to stop prescribing and administering the vaccine and remove remaining stock. The decision highlights that regulatory oversight must continue even after a product is approved. As new evidence emerges, the MHRA must reassess risks and act when necessary to protect patients and maintain public trust.

Other alerts show how quickly safety concerns can affect NHS operations. Quality-control problems with certain Nova Biomedical StatStrip ketone test strips, combined with supply disruptions, raised concerns about the availability of blood ketone testing. Healthcare organisations needed to check affected batches, assess stocks, consider alternative testing methods and prioritise patients at greatest risk, including those with suspected diabetic ketoacidosis.

The MHRA also warned that certain filter membranes used during continuous renal replacement therapy could absorb caspofungin, an antifungal medicine, potentially reducing its effectiveness. Responding to such alerts requires close coordination between pharmacists, procurement teams, laboratory services and clinicians. Tallon’s NHS experience makes this a particularly relevant test of his leadership: a warning has limited value unless healthcare organisations can translate it into timely action.

The same principle applies to adverse-event reporting. The MHRA’s MedSafetyWeek campaign, running from 2 to 8 November 2026, encourages patients and professionals to report suspected side effects and medical device incidents. Updates to the Yellow Card website and app aim to make reporting more accessible. Yet better digital tools alone cannot solve under-reporting. Clinicians need a simple reporting process and assurance that their submissions help inform regulatory decisions. Showing how reported evidence changes guidance could strengthen participation and trust.

Tallon must balance faster approvals with ongoing patient safety rather than treat them as separate goals. His experience in NHS operations, technology and organisational change gives him insight into how regulatory decisions affect healthcare delivery in practice. Faster assessments can support innovation and investment, but they must be matched by effective surveillance, clear communications and the capacity to respond when problems emerge.

The MHRA’s performance should be assessed not only by how quickly it approves medicines and medical devices, but also by how effectively it monitors their safety once they reach patients. It should also be measured by how effectively emerging risks are identified, communicated and managed across the health service. Tallon’s success will depend on maintaining both sides of that equation. For the NHS, patient safety is an essential part of successful innovation, not a separate responsibility. It is what makes innovation dependable.